Skip to main content
Top
Published in: Japanese Journal of Radiology 6/2019

01-06-2019 | Nephrectomy | Original Article

Cryoablation of renal cell carcinoma for patients with stage 4 or 5 non-dialysis chronic kidney disease

Authors: Hideo Gobara, Atsuhiro Nakatsuka, Kanichiro Shimizu, Takashi Yamanaka, Yusuke Matsui, Toshihiro Iguchi, Takao Hiraki, Koichiro Yamakado

Published in: Japanese Journal of Radiology | Issue 6/2019

Login to get access

Abstract

Purpose

To evaluate the safety and efficacy of cryoablation for renal cell carcinoma (RCC) in patients with stage 4 or 5 non-dialysis chronic kidney disease (CKD).

Materials and methods

This retrospective multicenter study included patients with maximum tumor diameter ≤ 4 cm, estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2, in whom cryoablation was performed percutaneously with curative intent between July 2011 and May 2016.

Results

Of 541 patients who underwent renal tumor cryoablation, 17 (3.1%; 4 women, 13 men; mean age 70.1 ± 10.6 years) with stage 4 or 5 non-dialysis CKD were included in this study. The pre-cryoablation eGFR was 22.5 ± 6.3 ml/min/1.73 m2. The mean tumor diameter was 2.8 ± 0.7 cm. No Grade 3 or higher adverse events occurred post-cryoablation. The eGFR at each time point was significantly lower than that before treatment. One patient required hemodialysis initiation at 21 months post-procedure. None of the patients showed residual RCC at their last follow-up.

Conclusion

Cryoablation of RCC is safe in patients with stage 4 or 5 non-dialysis CKD and yields treatment results comparable to those in patients without CKD. This treatment could be completed without the early initiation of hemodialysis after the procedure.
Literature
1.
go back to reference Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67:519–30.CrossRef Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67:519–30.CrossRef
3.
go back to reference Rabjerg M, Mikkelsen MN, Walter S, Marcussen N. Incidental renal neoplasms: is there a need for routine screening? A Danish single-center epidemiological study. APMIS. 2014;122:708–14.CrossRefPubMed Rabjerg M, Mikkelsen MN, Walter S, Marcussen N. Incidental renal neoplasms: is there a need for routine screening? A Danish single-center epidemiological study. APMIS. 2014;122:708–14.CrossRefPubMed
4.
go back to reference Schmit GD, Thompson RH, Kurup AN, Weisbrod AJ, Carter RE, Callstrom MR, et al. Percutaneous cryoablation of solitary sporadic renal cell carcinomas. BJU Int. 2012;110(11 Pt B):E526–31.CrossRefPubMed Schmit GD, Thompson RH, Kurup AN, Weisbrod AJ, Carter RE, Callstrom MR, et al. Percutaneous cryoablation of solitary sporadic renal cell carcinomas. BJU Int. 2012;110(11 Pt B):E526–31.CrossRefPubMed
5.
go back to reference Georgiades CS, Rodriguez R. Efficacy and safety of percutaneous cryoablation for stage 1A/B renal cell carcinoma: results of a prospective, single-arm, 5-year study. Cardiovasc Interv Radiol. 2014;37:1494–9.CrossRef Georgiades CS, Rodriguez R. Efficacy and safety of percutaneous cryoablation for stage 1A/B renal cell carcinoma: results of a prospective, single-arm, 5-year study. Cardiovasc Interv Radiol. 2014;37:1494–9.CrossRef
6.
go back to reference Aoun HD, Littrup PJ, Jaber M, Memon F, Adam B, Krycia M, et al. Percutaneous cryoablation of renal tumors: is it time for a new paradigm shift? J Vasc Interv Radiol. 2017;28:1363–70.CrossRefPubMed Aoun HD, Littrup PJ, Jaber M, Memon F, Adam B, Krycia M, et al. Percutaneous cryoablation of renal tumors: is it time for a new paradigm shift? J Vasc Interv Radiol. 2017;28:1363–70.CrossRefPubMed
7.
go back to reference Patel HD, Pierorazio PM, Johnson MH, Sharma R, Iyoha E, Allaf ME, et al. Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2017;12:1057–69.CrossRefPubMedPubMedCentral Patel HD, Pierorazio PM, Johnson MH, Sharma R, Iyoha E, Allaf ME, et al. Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2017;12:1057–69.CrossRefPubMedPubMedCentral
8.
go back to reference Wehrenberg-Klee E, Clark TW, Malkowicz SB, Soulen MC, Wein AJ, Mondschein JI, et al. Impact on renal function of percutaneous thermal ablation of renal masses in patients with preexisting chronic kidney disease. J Vasc Interv Radiol. 2012;23:41–5.CrossRefPubMed Wehrenberg-Klee E, Clark TW, Malkowicz SB, Soulen MC, Wein AJ, Mondschein JI, et al. Impact on renal function of percutaneous thermal ablation of renal masses in patients with preexisting chronic kidney disease. J Vasc Interv Radiol. 2012;23:41–5.CrossRefPubMed
9.
go back to reference Miyazaki M, Iguchi T, Takaki H, Yamanaka T, Tamura Y, Tokue H, et al. Ablation protocols and ancillary procedures in tumor ablation therapy: consensus from Japanese experts. Jpn J Radiol. 2016;34:647–56.CrossRefPubMed Miyazaki M, Iguchi T, Takaki H, Yamanaka T, Tamura Y, Tokue H, et al. Ablation protocols and ancillary procedures in tumor ablation therapy: consensus from Japanese experts. Jpn J Radiol. 2016;34:647–56.CrossRefPubMed
10.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef
11.
go back to reference Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182:844–53.CrossRefPubMed Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182:844–53.CrossRefPubMed
12.
go back to reference Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17:2034–47.CrossRef Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17:2034–47.CrossRef
13.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305. (Erratum in: N Engl J Med 2008;18:4).CrossRef Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305. (Erratum in: N Engl J Med 2008;18:4).CrossRef
14.
go back to reference Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis. 2008;52:661–71.CrossRefPubMed Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis. 2008;52:661–71.CrossRefPubMed
15.
go back to reference O'Hare AM, Bertenthal D, Walter LC, Garg AX, Covinsky K, Kaufman JS, et al. When to refer patients with chronic kidney disease for vascular access surgery: should age be a consideration? Kidney Int. 2007;71:555–61.CrossRefPubMed O'Hare AM, Bertenthal D, Walter LC, Garg AX, Covinsky K, Kaufman JS, et al. When to refer patients with chronic kidney disease for vascular access surgery: should age be a consideration? Kidney Int. 2007;71:555–61.CrossRefPubMed
16.
go back to reference Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913–24.CrossRef Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913–24.CrossRef
17.
go back to reference Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, et al. Kidney cancer, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2017;15:804–34.CrossRef Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, et al. Kidney cancer, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2017;15:804–34.CrossRef
18.
go back to reference Mason RJ, Atwell TD, Lohse C, Bhindi B, Weisbrod A, Boorjian SA, et al. Renal functional outcomes in patients undergoing percutaneous cryoablation or partial nephrectomy for a solitary renal mass. BJU Int. 2017;120:544–9.CrossRefPubMed Mason RJ, Atwell TD, Lohse C, Bhindi B, Weisbrod A, Boorjian SA, et al. Renal functional outcomes in patients undergoing percutaneous cryoablation or partial nephrectomy for a solitary renal mass. BJU Int. 2017;120:544–9.CrossRefPubMed
19.
go back to reference Maurice MJ, Ramirez D, Kara Ö, Malkoç E, Nelson RJ, Fareed K, et al. Optimum outcome achievement in partial nephrectomy for T1 renal masses: a contemporary analysis of open and robot-assisted cases. BJU Int. 2017;120:537–43.CrossRefPubMed Maurice MJ, Ramirez D, Kara Ö, Malkoç E, Nelson RJ, Fareed K, et al. Optimum outcome achievement in partial nephrectomy for T1 renal masses: a contemporary analysis of open and robot-assisted cases. BJU Int. 2017;120:537–43.CrossRefPubMed
20.
go back to reference Long JA, Bernhard JC, Bigot P, Lanchon C, Paparel P, Rioux-Leclercq N, et al. Partial nephrectomy versus ablative therapy for the treatment of renal tumors in an imperative setting. World J Urol. 2017;35:649–56.CrossRefPubMed Long JA, Bernhard JC, Bigot P, Lanchon C, Paparel P, Rioux-Leclercq N, et al. Partial nephrectomy versus ablative therapy for the treatment of renal tumors in an imperative setting. World J Urol. 2017;35:649–56.CrossRefPubMed
21.
go back to reference Georgiades C, Rodriguez R, Azene E, Weiss C, Chaux A, Gonzalez-Roibon N, et al. Determination of the nonlethal margin inside the visible "ice-ball" during percutaneous cryoablation of renal tissue. Cardiovasc Interv Radiol. 2013;36:783–90.CrossRef Georgiades C, Rodriguez R, Azene E, Weiss C, Chaux A, Gonzalez-Roibon N, et al. Determination of the nonlethal margin inside the visible "ice-ball" during percutaneous cryoablation of renal tissue. Cardiovasc Interv Radiol. 2013;36:783–90.CrossRef
22.
go back to reference Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333–400.CrossRefPubMed Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333–400.CrossRefPubMed
23.
go back to reference Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin N Am. 2009;47:827–81.CrossRef Thomsen HS. Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin N Am. 2009;47:827–81.CrossRef
24.
go back to reference Ellison JS, Montgomery JS, Hafez KS, Miller DC, He C, Wolf JS Jr, et al. Association of RENAL nephrometry score with outcomes of minimally invasive partial nephrectomy. Int J Urol. 2013;20:564–70.CrossRefPubMed Ellison JS, Montgomery JS, Hafez KS, Miller DC, He C, Wolf JS Jr, et al. Association of RENAL nephrometry score with outcomes of minimally invasive partial nephrectomy. Int J Urol. 2013;20:564–70.CrossRefPubMed
25.
go back to reference Roushias S, Vasdev N, Ganai B, Mafeld S, Rix D, Thomas D, et al. Can the R.e.N.a.L nephrometry score preoperatively predict postoperative clinical outcomes in patients undergoing open and laparoscopic partial nephrectomy? Curr Urol. 2013;7:90–7.CrossRefPubMedPubMedCentral Roushias S, Vasdev N, Ganai B, Mafeld S, Rix D, Thomas D, et al. Can the R.e.N.a.L nephrometry score preoperatively predict postoperative clinical outcomes in patients undergoing open and laparoscopic partial nephrectomy? Curr Urol. 2013;7:90–7.CrossRefPubMedPubMedCentral
26.
go back to reference Sisul DM, Liss MA, Palazzi KL, Briles K, Mehrazin R, Gold RE, et al. RENAL nephrometry score is associated with complications after renal cryoablation: a multicenter analysis. Urology. 2013;81:775–80.CrossRefPubMed Sisul DM, Liss MA, Palazzi KL, Briles K, Mehrazin R, Gold RE, et al. RENAL nephrometry score is associated with complications after renal cryoablation: a multicenter analysis. Urology. 2013;81:775–80.CrossRefPubMed
27.
go back to reference Blute Jr ML, Okhunov Z, Moreira DM, George AK, Sunday S, Lobko II K, et al. Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications. BJU Int. 2013;111(4 Pt B):E181–85.CrossRefPubMed Blute Jr ML, Okhunov Z, Moreira DM, George AK, Sunday S, Lobko II K, et al. Image-guided percutaneous renal cryoablation: preoperative risk factors for recurrence and complications. BJU Int. 2013;111(4 Pt B):E181–85.CrossRefPubMed
Metadata
Title
Cryoablation of renal cell carcinoma for patients with stage 4 or 5 non-dialysis chronic kidney disease
Authors
Hideo Gobara
Atsuhiro Nakatsuka
Kanichiro Shimizu
Takashi Yamanaka
Yusuke Matsui
Toshihiro Iguchi
Takao Hiraki
Koichiro Yamakado
Publication date
01-06-2019
Publisher
Springer Japan
Published in
Japanese Journal of Radiology / Issue 6/2019
Print ISSN: 1867-1071
Electronic ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-019-00821-7

Other articles of this Issue 6/2019

Japanese Journal of Radiology 6/2019 Go to the issue